<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papadimitriou, C.A.</style></author><author><style face="normal" font="default" size="100%">Zorzou, M.P.</style></author><author><style face="normal" font="default" size="100%">Markaki, S.</style></author><author><style face="normal" font="default" size="100%">Rodolakis, A.</style></author><author><style face="normal" font="default" size="100%">Voulgaris, Z.</style></author><author><style face="normal" font="default" size="100%">Bozas, G.</style></author><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Gika, D.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: Long-term results of a single institution experience</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Gynaecological Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adjuvant chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Anthracyclines</style></keyword><keyword><style  face="normal" font="default" size="100%">Early-stage uterine sarcomas</style></keyword><keyword><style  face="normal" font="default" size="100%">Ifosfamide</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247881829&amp;partnerID=40&amp;md5=f03dd4a22b7b9bcc125058aeb7b63e3d</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">28</style></volume><pages><style face="normal" font="default" size="100%">109 - 116</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Purpose of investigation: Uterine sarcomas are rare neoplasms characterized by a high rate of local recurrences and distant metastases. The role of chemotherapy in early-stage completely resected disease remains controversial. Methods: Thirty-one patients with Stage I or II uterine sarcomas, referred to our center for adjuvant chemotherapy, received anthracycline-based regimens. Seventeen (54.8%) patients received ifosfamide, etoposide and epirubicin, six (19.4%) were treated with doxorubicin and carboplatin, three (9.6%) were administered doxorubicin and ifosfamide, while five (16.1%) patients received various anthracycline-based regimens. Results: With a median follow-up of 82 months disease recurred in 12 (38.7%) patients. Five-year survival probability is estimated at 54%. Both median overall survival and time to progression for all patients have not been reached yet. Patients who received ifosfamide-containing regimens had a statistically significant benefit in overall survival (p ≤ 0.05) when compared with those treated with non-ifosfamide-containing regimens. Conclusion: Our data suggest a potential role for anthracycline- and ifosfamide-containing chemotherapy in the adjuvant setting for early-stage uterine sarcomas.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><notes><style face="normal" font="default" size="100%">Cited By :6Export Date: 21 February 2017</style></notes></record></records></xml>